Biogen Inc.
LEQEMBI IQLIK
Resolved
44days ago
FDA decision · May 24, 2026
What's at stake
The FDA's approval decision on LEQEMBI IQLIK for its lead indication is due May 24, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“LEQEMBI IQLIK subcutaneous treatment initiation granted FDA Priority Review with a PDUFA date of May 24, 2026”